Final notification to amend the Medical Devices Rules 2017 in order to exempt the requirement of TSEs and BSE certificates under certain conditions

## Report on the Medical Devices Fourth Amendment Rules, 2022 **1. Executive Summary:** This report analyzes the Medical Devices Fourth Amendment Rules, 2022, as published in the Gazette of India on June 15, 2022. This amendment modifies the Medical Devices Rules, 2017, specifically concerning the requirement for Transmissible Spongiform Encephalopathies (TSEs) or Bovine Spongiform Encephalopathy (BSE) certificates for medical devices. The amendment provides an exemption from this requirement if the animal source originates from a country recognized as having a negligible BSE risk by the World Organisation for Animal Health. This amendment aims to streamline the certification process for medical devices using animal-derived materials from low-risk countries, potentially reducing compliance burdens. **2. Introduction:** This report aims to provide a comprehensive overview of the Medical Devices Fourth Amendment Rules, 2022, based solely on the information provided in the official notification. The analysis focuses on the changes introduced, the rationale behind them, and their likely impact. **3. Policy Overview:** This is an amendment to the Medical Devices Rules, 2017. The core objective of this amendment, as inferred from the text, is to refine the regulatory requirements concerning biological safety assessments of medical devices, specifically concerning TSE/BSE risks, to allow for risk-based exemptions. **4. Background and Rationale:** This amendment appears to address the potential over-regulation of medical devices incorporating animal-derived materials, particularly those sourced from countries with negligible BSE risk. The original policy likely required TSE/BSE certificates regardless of the country of origin. The amendment aims to reduce unnecessary burdens and potentially expedite the approval process for devices deemed to be low risk based on international animal health standards. **5. Key Provisions / Changes:** This amendment focuses on a single, specific change within the Medical Devices Rules, 2017: * **Specific Part Amended:** Fourth Schedule, Part III, Appendix II, paragraph 7.4 relating to biological safety, in clause no. i. * **New Rule/Provision:** A proviso is inserted into the clause stating that TSE/BSE certificates are *not* required if the animal source originates from a country recognized as having negligible Bovine Spongiform Encephalopathy risk in accordance with the recommendations of the World Organisation for Animal Health. * **Difference/Effect:** The original rule likely required TSE/BSE certificates for *all* animal-derived materials. This amendment introduces an *exemption* based on the country of origin and its BSE risk classification by the World Organisation for Animal Health. This potentially removes a requirement for documentation where the risk is deemed negligible by an international body. **6. Target Audience and Stakeholders:** The primary target audience and stakeholders affected by this amendment include: * Manufacturers of medical devices that utilize animal-derived materials. * Regulatory bodies involved in the assessment and approval of medical devices (e.g., the Ministry of Health and Family Welfare, the Drugs Technical Advisory Board). * Importers and distributors of medical devices that utilize animal-derived materials. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** The Ministry of Health and Family Welfare, in consultation with the Drugs Technical Advisory Board, is responsible for implementing and enforcing these rules. * **Timelines or Procedures:** The rules came into force on the date of their publication in the Official Gazette (June 15, 2022). Further specific procedures for determining "negligible Bovine Spongiform Encephalopathy risk" are not outlined in this text and would likely be detailed in subsequent guidance documents. * **Amendment-Specific Implementation:** Implementation of the amendment will require regulatory bodies to recognize and accept the BSE risk classifications provided by the World Organisation for Animal Health. Medical device manufacturers will need to provide documentation demonstrating that their animal-derived materials originate from countries with negligible BSE risk, as defined by the World Organisation for Animal Health, to qualify for the exemption. **8. Expected Outcomes / Impact of Changes:** The intended outcome of this amendment is to streamline the regulatory process for medical devices utilizing animal-derived materials sourced from low-risk countries. This is expected to: * Reduce the compliance burden for manufacturers by eliminating the need for TSE/BSE certificates in specific cases. * Potentially expedite the approval process for affected medical devices. * Align Indian regulations with international standards and risk-based approaches to biological safety. **9. Conclusion:** The Medical Devices Fourth Amendment Rules, 2022, represents a targeted adjustment to existing regulations, introducing a risk-based exemption from TSE/BSE certification requirements for medical devices using animal-derived materials. This amendment is significant as it reflects a move towards a more efficient and internationally harmonized regulatory framework for medical devices in India. It is crucial for affected stakeholders, particularly medical device manufacturers, to understand and comply with the amended regulations and align their practices with the recommendations of the World Organisation for Animal Health regarding BSE risk.

Key Entities Referenced